Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001
A multicentre surveillance study comprising 26 laboratories located in Austria, Germany, and Switzerland was carried out in November 2001. A total of 787 isolates of Staphylococcus aureus and 456 isolates of Staphylococcus epidermidis mainly recovered from hospitalised patients, were tested. MICs fo...
Gespeichert in:
| Veröffentlicht in: | International journal of antimicrobial agents 2004-06, Vol.23 (6), p.577-581 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 581 |
|---|---|
| container_issue | 6 |
| container_start_page | 577 |
| container_title | International journal of antimicrobial agents |
| container_volume | 23 |
| creator | Kresken, Michael Hafner, Dieter Schmitz, Franz-Josef Wichelhaus, Thomas A |
| description | A multicentre surveillance study comprising 26 laboratories located in Austria, Germany, and Switzerland was carried out in November 2001. A total of 787 isolates of
Staphylococcus aureus and 456 isolates of
Staphylococcus epidermidis mainly recovered from hospitalised patients, were tested. MICs for mupirocin were determined using the broth microdilution procedure. Breakpoints were ≤4
mg/l (susceptible), 8–256
mg/l (low-level resistance) and ≥512
mg/l (high-level resistance). Rates of low- and high-level resistances were 2.9 and 0.9% in
S. aureus, and 9.4 and 3.3% in
S. epidermidis, respectively. Mupirocin resistance was almost exclusively observed in oxacillin-resistant isolates of
S. aureus (MRSA) and
S. epidermidis (MRSE). High-level mupirocin resistance was detected in 3.1 and 4.5% of MRSA and MRSE, respectively. |
| doi_str_mv | 10.1016/j.ijantimicag.2003.11.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72020678</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924857904000949</els_id><sourcerecordid>72020678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-3fa9314fa511a6caa47c77295b7644f499be02eefa670dbd49476d2265bdd8c23</originalsourceid><addsrcrecordid>eNqNkctu1DAUhiMEokPhFVBY0BUJtuPECbtqVC5SJSoG1pZjnxCPnDjYzkh5WZ4FpxnUihWro2N_5_b_SfIGoxwjXL0_5vooxqAHLcXPnCBU5BjnCLEnyQ7XjGSswcXTZIcaQrO6ZM1F8sL7I0K4LGj5PLnAJW4oJvUu-X3n4CQMjBJS26XDPGlnpR5TB177INb3mEmjxzjMpNpbIwL4FT4EMfWLsdJKOftUzA7WMKp_f2DSCtyglfYf1sazCfcNQg_p9XaHs62O7b89TD3M7gTamC0Js1r-ltyJ2WQ3vTNa9tkhbgthSTvr0n0Pg42EE9PyLo264JfJs04YD6_O8TL58fHm-_5zdvv105f99W0mKSpCVnSiKTDtRImxqKQQlEnGSFO2rKK0o03TAiIAnagYUq2iDWWVIqQqW6VqSYrL5GrrOzn7awYf-KC9hHV7sLPnjCCCKlZHsNnAeLH3Djo-OT0It3CM-GouP_JH5vLVXI4xj-bG2tfnIXM7gHqoPLsZgbdnQPhoVueidto_4uqyqO-5_cZBlOSkwXEfRYw6K-1ABq6s_o91_gB6fM8f</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72020678</pqid></control><display><type>article</type><title>Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Kresken, Michael ; Hafner, Dieter ; Schmitz, Franz-Josef ; Wichelhaus, Thomas A</creator><creatorcontrib>Kresken, Michael ; Hafner, Dieter ; Schmitz, Franz-Josef ; Wichelhaus, Thomas A ; on behalf of the Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy ; Paul-Ehrlich-Society for Chemotherapy</creatorcontrib><description>A multicentre surveillance study comprising 26 laboratories located in Austria, Germany, and Switzerland was carried out in November 2001. A total of 787 isolates of
Staphylococcus aureus and 456 isolates of
Staphylococcus epidermidis mainly recovered from hospitalised patients, were tested. MICs for mupirocin were determined using the broth microdilution procedure. Breakpoints were ≤4
mg/l (susceptible), 8–256
mg/l (low-level resistance) and ≥512
mg/l (high-level resistance). Rates of low- and high-level resistances were 2.9 and 0.9% in
S. aureus, and 9.4 and 3.3% in
S. epidermidis, respectively. Mupirocin resistance was almost exclusively observed in oxacillin-resistant isolates of
S. aureus (MRSA) and
S. epidermidis (MRSE). High-level mupirocin resistance was detected in 3.1 and 4.5% of MRSA and MRSE, respectively.</description><identifier>ISSN: 0924-8579</identifier><identifier>EISSN: 1872-7913</identifier><identifier>DOI: 10.1016/j.ijantimicag.2003.11.007</identifier><identifier>PMID: 15194128</identifier><language>eng</language><publisher>London: Elsevier B.V</publisher><subject>Anti-Bacterial Agents - pharmacology ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Austria ; Biological and medical sciences ; Drug Resistance, Bacterial ; Germany ; Humans ; Medical sciences ; Methicillin Resistance ; Microbial Sensitivity Tests ; Mupirocin ; Mupirocin - pharmacology ; Oxacillin - pharmacology ; Pharmacology. Drug treatments ; Resistance ; Staphylococcal Infections - microbiology ; Staphylococcus aureus ; Staphylococcus aureus - drug effects ; Staphylococcus aureus - isolation & purification ; Staphylococcus epidermidis ; Staphylococcus epidermidis - drug effects ; Staphylococcus epidermidis - isolation & purification ; Switzerland</subject><ispartof>International journal of antimicrobial agents, 2004-06, Vol.23 (6), p.577-581</ispartof><rights>2004 Elsevier B.V. and the International Society of Chemotherapy</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2004 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-3fa9314fa511a6caa47c77295b7644f499be02eefa670dbd49476d2265bdd8c23</citedby><cites>FETCH-LOGICAL-c403t-3fa9314fa511a6caa47c77295b7644f499be02eefa670dbd49476d2265bdd8c23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijantimicag.2003.11.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15853828$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15194128$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kresken, Michael</creatorcontrib><creatorcontrib>Hafner, Dieter</creatorcontrib><creatorcontrib>Schmitz, Franz-Josef</creatorcontrib><creatorcontrib>Wichelhaus, Thomas A</creatorcontrib><creatorcontrib>on behalf of the Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy</creatorcontrib><creatorcontrib>Paul-Ehrlich-Society for Chemotherapy</creatorcontrib><title>Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001</title><title>International journal of antimicrobial agents</title><addtitle>Int J Antimicrob Agents</addtitle><description>A multicentre surveillance study comprising 26 laboratories located in Austria, Germany, and Switzerland was carried out in November 2001. A total of 787 isolates of
Staphylococcus aureus and 456 isolates of
Staphylococcus epidermidis mainly recovered from hospitalised patients, were tested. MICs for mupirocin were determined using the broth microdilution procedure. Breakpoints were ≤4
mg/l (susceptible), 8–256
mg/l (low-level resistance) and ≥512
mg/l (high-level resistance). Rates of low- and high-level resistances were 2.9 and 0.9% in
S. aureus, and 9.4 and 3.3% in
S. epidermidis, respectively. Mupirocin resistance was almost exclusively observed in oxacillin-resistant isolates of
S. aureus (MRSA) and
S. epidermidis (MRSE). High-level mupirocin resistance was detected in 3.1 and 4.5% of MRSA and MRSE, respectively.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Austria</subject><subject>Biological and medical sciences</subject><subject>Drug Resistance, Bacterial</subject><subject>Germany</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Methicillin Resistance</subject><subject>Microbial Sensitivity Tests</subject><subject>Mupirocin</subject><subject>Mupirocin - pharmacology</subject><subject>Oxacillin - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Resistance</subject><subject>Staphylococcal Infections - microbiology</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Staphylococcus aureus - isolation & purification</subject><subject>Staphylococcus epidermidis</subject><subject>Staphylococcus epidermidis - drug effects</subject><subject>Staphylococcus epidermidis - isolation & purification</subject><subject>Switzerland</subject><issn>0924-8579</issn><issn>1872-7913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkctu1DAUhiMEokPhFVBY0BUJtuPECbtqVC5SJSoG1pZjnxCPnDjYzkh5WZ4FpxnUihWro2N_5_b_SfIGoxwjXL0_5vooxqAHLcXPnCBU5BjnCLEnyQ7XjGSswcXTZIcaQrO6ZM1F8sL7I0K4LGj5PLnAJW4oJvUu-X3n4CQMjBJS26XDPGlnpR5TB177INb3mEmjxzjMpNpbIwL4FT4EMfWLsdJKOftUzA7WMKp_f2DSCtyglfYf1sazCfcNQg_p9XaHs62O7b89TD3M7gTamC0Js1r-ltyJ2WQ3vTNa9tkhbgthSTvr0n0Pg42EE9PyLo264JfJs04YD6_O8TL58fHm-_5zdvv105f99W0mKSpCVnSiKTDtRImxqKQQlEnGSFO2rKK0o03TAiIAnagYUq2iDWWVIqQqW6VqSYrL5GrrOzn7awYf-KC9hHV7sLPnjCCCKlZHsNnAeLH3Djo-OT0It3CM-GouP_JH5vLVXI4xj-bG2tfnIXM7gHqoPLsZgbdnQPhoVueidto_4uqyqO-5_cZBlOSkwXEfRYw6K-1ABq6s_o91_gB6fM8f</recordid><startdate>20040601</startdate><enddate>20040601</enddate><creator>Kresken, Michael</creator><creator>Hafner, Dieter</creator><creator>Schmitz, Franz-Josef</creator><creator>Wichelhaus, Thomas A</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040601</creationdate><title>Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001</title><author>Kresken, Michael ; Hafner, Dieter ; Schmitz, Franz-Josef ; Wichelhaus, Thomas A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-3fa9314fa511a6caa47c77295b7644f499be02eefa670dbd49476d2265bdd8c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Austria</topic><topic>Biological and medical sciences</topic><topic>Drug Resistance, Bacterial</topic><topic>Germany</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Methicillin Resistance</topic><topic>Microbial Sensitivity Tests</topic><topic>Mupirocin</topic><topic>Mupirocin - pharmacology</topic><topic>Oxacillin - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Resistance</topic><topic>Staphylococcal Infections - microbiology</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Staphylococcus aureus - isolation & purification</topic><topic>Staphylococcus epidermidis</topic><topic>Staphylococcus epidermidis - drug effects</topic><topic>Staphylococcus epidermidis - isolation & purification</topic><topic>Switzerland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kresken, Michael</creatorcontrib><creatorcontrib>Hafner, Dieter</creatorcontrib><creatorcontrib>Schmitz, Franz-Josef</creatorcontrib><creatorcontrib>Wichelhaus, Thomas A</creatorcontrib><creatorcontrib>on behalf of the Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy</creatorcontrib><creatorcontrib>Paul-Ehrlich-Society for Chemotherapy</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kresken, Michael</au><au>Hafner, Dieter</au><au>Schmitz, Franz-Josef</au><au>Wichelhaus, Thomas A</au><aucorp>on behalf of the Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy</aucorp><aucorp>Paul-Ehrlich-Society for Chemotherapy</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001</atitle><jtitle>International journal of antimicrobial agents</jtitle><addtitle>Int J Antimicrob Agents</addtitle><date>2004-06-01</date><risdate>2004</risdate><volume>23</volume><issue>6</issue><spage>577</spage><epage>581</epage><pages>577-581</pages><issn>0924-8579</issn><eissn>1872-7913</eissn><abstract>A multicentre surveillance study comprising 26 laboratories located in Austria, Germany, and Switzerland was carried out in November 2001. A total of 787 isolates of
Staphylococcus aureus and 456 isolates of
Staphylococcus epidermidis mainly recovered from hospitalised patients, were tested. MICs for mupirocin were determined using the broth microdilution procedure. Breakpoints were ≤4
mg/l (susceptible), 8–256
mg/l (low-level resistance) and ≥512
mg/l (high-level resistance). Rates of low- and high-level resistances were 2.9 and 0.9% in
S. aureus, and 9.4 and 3.3% in
S. epidermidis, respectively. Mupirocin resistance was almost exclusively observed in oxacillin-resistant isolates of
S. aureus (MRSA) and
S. epidermidis (MRSE). High-level mupirocin resistance was detected in 3.1 and 4.5% of MRSA and MRSE, respectively.</abstract><cop>London</cop><cop>Amsterdam</cop><cop>New York, NY</cop><pub>Elsevier B.V</pub><pmid>15194128</pmid><doi>10.1016/j.ijantimicag.2003.11.007</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0924-8579 |
| ispartof | International journal of antimicrobial agents, 2004-06, Vol.23 (6), p.577-581 |
| issn | 0924-8579 1872-7913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72020678 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Anti-Bacterial Agents - pharmacology Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Austria Biological and medical sciences Drug Resistance, Bacterial Germany Humans Medical sciences Methicillin Resistance Microbial Sensitivity Tests Mupirocin Mupirocin - pharmacology Oxacillin - pharmacology Pharmacology. Drug treatments Resistance Staphylococcal Infections - microbiology Staphylococcus aureus Staphylococcus aureus - drug effects Staphylococcus aureus - isolation & purification Staphylococcus epidermidis Staphylococcus epidermidis - drug effects Staphylococcus epidermidis - isolation & purification Switzerland |
| title | Prevalence of mupirocin resistance in clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis: results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy, 2001 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T13%3A40%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20mupirocin%20resistance%20in%20clinical%20isolates%20of%20Staphylococcus%20aureus%20and%20Staphylococcus%20epidermidis:%20results%20of%20the%20Antimicrobial%20Resistance%20Surveillance%20Study%20of%20the%20Paul-Ehrlich-Society%20for%20Chemotherapy,%202001&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=Kresken,%20Michael&rft.aucorp=on%20behalf%20of%20the%20Working%20Group%20for%20Antimicrobial%20Resistance%20of%20the%20Paul-Ehrlich-Society%20for%20Chemotherapy&rft.date=2004-06-01&rft.volume=23&rft.issue=6&rft.spage=577&rft.epage=581&rft.pages=577-581&rft.issn=0924-8579&rft.eissn=1872-7913&rft_id=info:doi/10.1016/j.ijantimicag.2003.11.007&rft_dat=%3Cproquest_cross%3E72020678%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72020678&rft_id=info:pmid/15194128&rft_els_id=S0924857904000949&rfr_iscdi=true |